Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice

Boehringer Ingelheim

Status: Completed

Conditions: Parkinson's Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT01061567

248.675

Details and patient eligibility

About

The general aim of this non-interventional study is to assess the safety and efficacy of pramipexole extended release in patients with Parkinson's disease in routine clinical practice.

Enrollment: 1,814 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Early and advanced idiopathic Parkinson's disease
• Male and female patients over 18 years of age
• Indication for treatment with pramipexole ER according to Summary of Product Characteristics (SmPC)

Exclusion criteria

• Ongoing treatment with pramipexole ER
• Exclusion criteria in line with the pramipexole ER SmPC:

In particular hypersensitivity to pramipexole or to any of the excipients and pregnancy and lactation as stated in the SmPC.

Trial design

1,814 participants in 1 patient group

Male and female patients with Parkinson's disease